Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Jan 8, 2009

Premium
Title: Methods for Identifying Genes That Mediate a Response of a Living Cell to an Agent
 
Number: 20090004645
 
Filed: April 12, 2005 PCT Filed: April 12, 2005
 
Lead Inventor: Mao Mao, Rosetta Inpharmatics (Merck)
 
The invention, the patent application’s abstract states, comprises “methods for determining whether a gene mediates the response of a living cell to an agent,” as well as “methods to identify a mammalian subject responsive to a KSP inhibitor.”
 
The application specifically claims the use of RNAi molecules to help determine the response of the cell to an agent.
 

 
Title: Pre-miRNA Loop-Modulated Target Regulation
 
Number: 20090004668
 
Filed: June 20, 2008
 
Lead Inventor: Chang-Zheng Chen, Leland Stanford Junior University
 
“By employing essential nucleotides from both the stem and loop of precursor-miRNA, greater specificity is achieved as to the mRNAs that are repressed,” the patent application’s abstract states. “It is found that besides the seed sequence of the stem of the pre-miRNA, nucleotides in the loop affect the activity and specificity of the [precursor] and the processing and binding to target mRNA. By using both sequences in the natural pre-miRNA or modified mimetics, one can screen for cellular miRNA expression, modulate cell properties with greater specificity, and investigate cellular activity as to phenotype and response to external stimuli in the presence and absence of target protein expression.”
 

 
Title: Method for the Production of Suitable DNA Constructs for Specific Inhibition of Gene Expression by RNA Interference
 
Number: 20090004703
 
Filed: Dec. 28, 2004 PCT Filed: Dec. 28, 2004
 
Inventor: Matthias Schroff, Mologen
 
According to the patent application’s abstract, “the invention relates to a method for the production of vectors which, following transfection thereof in eukaryotic cells, are suitable for targeted inhibition of the formation of defined proteins therein by RNA interference. The method for the production of such vectors does not include any PCR steps … [but] is a three-step procedure in a single reaction vessel and can be carried out within a few hours. Thus, a method is provided which allows very easy testing of a wide variety of siRNA sequences for their functionality within a very short time,” the abstract adds. “Screening processes utilizing the rapid and uncomplicated production of vectors with the aid of said kit can be performed in a cost- and time-saving manner. Another advantage of vectors thus produced is their small size which, among other things, facilitates transfection.”
 

 
Title: Use of the microRNA miR-1 for the Treatment, Prevention, and Diagnosis of Cardiac Conditions
 
Number: 20090005336
 
Filed: May 8, 2008
 
Inventor: Zhiguo Wang, University of Montreal
 
“Among [the more than] 300 miRNAs known to date, miR-1 is considered muscle-specific,” the patent application’s abstract states. “Here we show that that miR-1 [is] over-expressed in individuals with coronary artery disease, and when over-expressed it exacerbated arrhythmogenesis in both infarcted and normal hearts of rats, whereas elimination of miR-1 by its antisense inhibitor relieved it. MiR-1 rendered slowed conduction and depolarized membrane by post-transcriptionally repressing KCNJ2 and GJA1 genes, likely accounting for its arrhythmogenic potential. Thus, miR-1 may have important pathophysiological functions in heart, being a novel antiarrhythmic target useful in the treatment and prevention of various cardiac pathologies.”
 

 
Title: siRNA Targeting Neuropilin 1
 
Number: 20090005547
 
Filed: July 27, 2007
 
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
 
“Efficient sequence-specific gene silencing is possible through the use of siRNA technology,” the patent application’s abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to NRP1.”
 

 
Title: siRNA Targeting Nuclear Receptor Interacting Protein 1
 
Number: 20090005548
 
Filed: July 27, 2007
 
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
 
“Efficient sequence-specific gene silencing is possible through the use of siRNA technology,” the patent application’s abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to NRIP1.”
 

 
Title: Processes and Reagents for Desilylation of Oligonucleotides
 
Number: 20090005549
 
Filed: March 18, 2008
 
Lead Inventor: Muthiah Manoharan, Alnylam Pharmaceuticals
 
The invention, the patent application’s abstract states, “relates to processes and reagents for oligonucleotide synthesis and purification. One aspect of the … invention relates to compounds useful for activating phosphoramidites in oligonucleotide synthesis … [while] another aspect … to a method of preparing oligonucleotides via the phosphoramidite method using an activator of the invention.” The abstract notes that another aspect of the invention “relates to sulfur-transfer agents,” and in a preferred embodiment, the sulfur-transfer agent is a 3-amino-1,2,4-dithiazolidine-5-one.
 
“Another aspect of the … invention relates to a method of preparing a phosphorothioate by treating a phosphite with a sulfur-transfer reagent of the invention … [and] in a preferred embodiment, the sulfur-transfer agent is a 3-amino-1,2,4-dithiazolidine-5-one,” the abstract states. “Another aspect of the … invention relates to compounds that scavenge acrylonitrile produced during the deprotection of phosphate groups bearing ethylnitrile protecting groups, [and] in a preferred embodiment, the acrylonitrile scavenger is a polymer-bound thiol.”
 
Yet another aspect of the invention relates to “agents used to oxidize a phosphite to a phosphate,” the abstract states, adding that in a preferred embodiment, the oxidizing agent is sodium chlorite, chloroamine, or pyridine-N-oxide.
 
“Another aspect of the … invention relates to methods of purifying an oligonucleotide by annealing a first single-stranded oligonucleotide and second single-stranded oligonucleotide to form a double-stranded oligonucleotide; and subjecting the double-stranded oligonucleotide to chromatographic purification,” the abstract states. “In a preferred embodiment, the chromatographic purification is high-performance liquid chromatography.”

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.